

## Publikační činnost Kliniky hematoonkologie za rok 2022

### **Publikace in extenso:**

#### **Články v časopisech s IF (IF 495)**

- 1 Venglar O, Bago JR, Motaïs B, Hajek R, Jelinek T. Natural Killer Cells in the Malignant Niche of Multiple Myeloma. *Front Immunol.* 2022 Jan 11;12:816499.
- 2 Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Radocha J, Simicek M, Hajek R. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. *Leukemia*. 2022 Jan;36(1):288-291.
- 3 Martina Zátopková, Tereza Ševčíková, Viola Fanfani, Zuzana Chyra, Lucie Rihova, Renata Bezdekova, David Žihala, Kateřina Growková, Jana Filipova, Lucie Černá, Lucie Broskevičová, Fedor Kryukov, Jiří Minařík, Jana Smejkalová, Vladimir Maisnar, Lubica Harvanová, Ludek Pour, Alexandra Jungova, Tereza Popková, Juli Rodriguez Bago, Anjana Anilkumar Sithara, Matous Hrdinka, Tomas Jelinek, Michal Šimíček, Giovanni Stracquadanio, Roman Hajek. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. *Blood Adv.* 2022 Jan 25;6(2):368-372.
- 4 Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, Brozova L, Jarkovsky J, Spicka I, Straub J, Pavlicek P, Jungova A, Jelinek T, Sandecka V, Maisnar V, Hajek R, Pour L. Identification of patients at high risk of secondary extramedullary multiple myeloma development. *Br J Haematol.* 2022 Feb;196(4):954-962.
- 5 Delimpasi S, Mateos MV, Auner HW, Gavriatopoulou M, Dimopoulos MA, Quach H, Pylypenko H, Hájek R, Leleu X, Dolai TK, Sinha DK, Venner CP, Benjamin R, Garg MK, Doronin V, Levy Y, Moreau P, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. *Am J Hematol.* 2022 Mar 1;97(3):E83-E86.
- 6 Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U; EHA Guidelines Committee ESMO Guidelines Committee. Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. *Ann Oncol.* 2022 Jan;33(1):117.
- 7 Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. *Lancet Haematol.* 2022 Feb;9(2):e98-e110.
- 8 Demel I, Koristek Z, Motaïs B, Hájek R, Jelínek T. Natural killer cells – innate immune system as a part of adaptive immunotherapy in hematological malignancies. *Am J Hematol.* 2022 Jun 1;97(6):802-817
- 9 Clay-Gilmour A, Chattopadhyay S, Hildebrandt MAT, Thomsen H, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Manasanch EE, Norman A, Kumar S, Rajkumar SV, Slager S, Försti A, Vachon CM, Hemminki K. Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. *Blood Cancer J.* 2022 Apr 13;12(4):60
- 10 Hradská K, Popková T, Skořupová M, Mihályová J, Jelínek T, Lančová J, Schellong N, Hájek R. Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine. *Cancer Manag Res.* 2022 May 4;14:1655-1661

- 11 Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. *ESMO Open*. 2022 Apr;7(2):100403
- 12 Šušol O, Hájková B, Zelená H, Hájek R. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. *Br J Haematol*. 2022 May;197(3):302-305
- 13 Martin TG, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risso ML, Asset G, Macé S, van de Velde H, Moreau P. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. *Blood Adv*. 2022 Aug 9;6(15):4506-4515.
- 14 Barbora Weinbergerová, Ivo Demel, Benjamin Víšek, Jan Válka, Martin Čerňan, Pavel Jindra, Jan Novák, Lukáš Stejskal, Flóra Kováčsová, Tomáš Kabut, Tomáš Szotkowski, Roman Hájek, Pavel Žák, Petr Cetkovský, Zdeněk Král, Jiří Mayer Successful Early Use of Anti-SARS-CoV-2 Monoclonal Neutralizing Antibodies in COVID-19 Infected Hemato-Oncological Patients – A Czech Multicenter Experience, *Hematol Oncol*. 2022 Apr;40(2):280-286
- 15 Botta C, Maia C, Garcés JJ, Termini R, Perez C, Manrique I, Burgos L, Zabaleta A, Alignani D, Sarvide S, Merino J, Puig N, Cedena MT, Rossi M, Tassone P, Gentile M, Correale P, Borrello I, Terpos E, Jelinek T, Paiva A, Roccaro A, Goldschmidt H, Avet-Loiseau H, Rosinol L, Mateos MV, Martinez-Lopez J, Lahuerta JJ, Bladé J, San-Miguel JF, Paiva B. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. *Blood Adv*. 2022 Jan 25;6(2):690-703.
- 16 Mocikova H, Pytlík R, Benesova K, Janikova A, Duras J, Sykorova A, Steinerova K, Prochazka V, Campr V, Belada D, Trneny M. Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry. *Front Oncol*. 2022 May 12;12:874462.
- 17 Janikova A, Michalka J, Chloupkova R, Kopalova N, Campr V, Kamaradova K, Kren L, Belada D, Benesova K, Dlouha J, Klener P, Procházka V, Mocikova H, Duras J, Trneny M. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). *Ann Hematol*. 2022 Apr;101(4):789-798.
- 18 Vodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, Steinerova K, Duras J, Karban J, Hanackova V, Sykorova A, Obr A, Trneny M. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. *Eur J Haematol*. 2022 Aug;109(2):162-165.
- 19 Beksac M, Spicka I, Hajek R, Bringhen S, Jelínek T, Martin T, Mikala G, Moreau P, Symeonidis A, Rawlings AM, van de Velde H, Richardson PG. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. *Leuk Res*. 2022 Nov;122:106948.
- 20 Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Alonso Fernandez R, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. *Clin Cancer Res*. 2022 Oct 25:CCR-22-1161
- 21 Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim JS, Shu N, Hu X, Li C, Usmani SZ. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. *Br J Haematol*. 2022 Sep;198(6):988-993
- 22 Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, Pour L, Croockewit S, Corradini P, Patriarca F, Wu K, Droogendijk J, Bos G, Hajek R, Teresa Petrucci M, Ypma P, Zoyer N, Minnema MC, Boccadoro M. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. *Hemasphere*. 2022 Sep 30;6(10):e786.
- 23 Termini R, Zihala D, Terpos E, Pérez-Montaña A, Jelinek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodríguez S, Moreno C, Perez C, Maia C, Martin-Sánchez E, Guerrero C, Botta C, Garcés JJ, Lopez A, Tamariz-Amador LE, Prósper F, Bargay J, Cabezudo ME, Ocio EM, Hájek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A, Geraldès C, Matos Silva H, Gomez C, De Arriba F, Ludwig H, García-Guiñon A, Casanova M, Alegre A, Cabañas V, Sirvent M, Oriol A, De la Rubia J, Hernández-Rivas JÁ, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. *Clin Cancer Res*. 2022 Sep 8:CCR-22-1594

- 24 Minarik J, Radocha J, Jungova A, Straub J, Jelinek T, Pika T, Pour L, Pavlicek P, Harvanova L, Pospisilova L, Krhovska P, Novakova D, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Maisnar V, Hajek R. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. *Cancers (Basel)*. 2022 Oct 21;14(20):5165.
- 25 David J Kuter, Merlin Efraim, Jiri Mayer, Marek Trnáček, Vickie McDonald, Robert Bird, Thomas Regenbogen, Mamta Garg, Zane Kaplan, Nikolay Tzvetkov, Philip Y Choi, A J Gerard Jansen, Milan Kostal, Ross Baker, Jaromir Gumulec, Eun-Ju Lee, Ilona Cunningham, Isaac Goncalves, Margaret Warner, Ralph Boccia, Terry Gernsheimer, Waleed Ghaniya, Olga Bandman, Regan Burns, Ann Neale, Dolca Thomas, Puneet Arora, Beiyao Zheng, Nichola Cooper. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. *New England Journal of Medicine* 2022 April 14, 386 (15): 1421-1431
- 26 Alexander Vdovin, Tomas Jelinek, David Zihala, Tereza Sevcikova, Michal Durech, Hana Sahinbegovic, Renata Snaurova, Dhwani Radhakrishnan, Marcello Turi, Zuzana Chyra, Tereza Popkova, Ondrej Venglar, Matous Hrdinka, Roman Hajek, Michal Simicek. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. *Nat Commun*. 2022 Nov 10;13(1):6820.
- 27 Hurník P, Chyra Z, Ševčíková T, Štembírek J, Trtková KS, Gaykalova DA, Buchtová M, Hrubá E. Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma. *Front Genet*. 2022 Apr 27;13:848557
- 28 Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A. Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. *Cells*. 2022 Aug 14;11(16):2519
- 29 Stork M, Sevcikova S, Jelinek T, Minarik J, Radocha J, Pika T, Lenka Pospisilova, Ivan Spicka, Jan Straub, Petr Pavlicek, Alexandra Jungova, Zdenka Knechtova, Viera Sandecka, Vladimir Maisnar, Roman Hajek, Lukáš Pour. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. *Biomedicines* 2022; 10: 2535
- 30 Infante MS, Salmanton-García J, Fernández-Cruz A, Marchesi F, Jaksic O, Weinbergerová B, Besson C, Duarte RF, Itri F, Valković T, Szotkovski T, Busca A, Guidetti A, Glenthøj A, Collins GP, Bonuomo V, Sili U, Seval GC, Machado M, Cordoba R, Blennow O, Abu-Zeinah G, Lamure S, Kulasekararaj A, Falces-Romero I, Cattaneo C, Van Doesum J, Piukovics K, Omrani AS, Magliano G, Ledoux MP, de Ramon C, Cabrita A, Verga L, López-García A, Da Silva MG, Stojanoski Z, Meers S, Lahmer T, Martín-Pérez S, Dávila-Vals J, Van Praet J, Samarkos M, Bilgin YM, Karlsson LK, Batinić J, Nordlander A, Schönlein M, Hoenigl M, Ráčil Z, Mladenović M, Hanakova M, Zambrotta GPM, De Jonge N, Adžić-Vukičević T, Nunes-Rodrigues R, Prezioso L, Navrátil M, Marchetti M, Cuccaro A, Calbacho M, Giordano A, Cornely OA, Hernández-Rivas, Pagano L. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). *Front Oncol*. 2022 Oct 3;12:992137.
- 31 Dobiáš R, Jaworská P, Skopelidou V, Strakoš J, Višňovská D, Káňová M, Škriba A, Lysková P, Bartek T, Janíčková I, Kozel R, Cwiková L, Vrba Z, Navrátil M, Martinek J, Coufalová P, Krejčí E, Ulmann V, Raška M, Stevens DA, Havlíček V. Distinguishing Invasive from Chronic Pulmonary Infections: Host Pentraxin 3 and Fungal Siderophores in Bronchoalveolar Lavage Fluids. *Journal of Fungi*. 2022; 8(11):1194
- 32 Renata Snaurova, Alexandr Vdovin, Michal Durech, Jakub Nezval, David Zihala, Tomas Jelinek, Roman Hajek, and Michal Simicek. Deubiquitinase OTUD1 resolves stalled translation on polyA and rare codon rich mRNAs. *Mol Cell Biol*. 2022 Nov 29;e0026522.
- 33 Sahinbegovic, Hana, Stephanie Andres, Sabine Langer-Freitag, Aspasia Divane, Fotini Ieremiadou, Senad Mehmedbasic, and Aida Catic. Genome wide noninvasive prenatal testing detects microduplication of the distal end of chromosome 15 in a fetus: a case report. *Mol Cytogenet*. 2022 Apr 2;15(1):16
- 34 Vlachová, Monika, Jana Gregorová, Petra Vychytílová-Faltejsková, Natalia Anna Gablo, Lenka Radová, Lenka Pospíšilová, Martina Almáši, Martin Štok, Zdeňka Knechtová, Jiří Minařík, Tereza Popková, Tomáš Jelínek, Roman Hájek, Luděk Pour, Lucie Říhová, a Sabina Ševčíková. 2022. „Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma“. *International Journal of Molecular Sciences* 23(23):14765
- 35 Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksaç, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra Cornelisse, Rosella Troia, Stefania Oliva, Vincent van de Velden, KaLung Wu, Paula F Ypma, Gerard Bos, Mark-David Levin, Luca Pour, Christoph Driessen, Annemiek Broijl, Alexandra Croockewit, Monique C Minnema, Anders Waage, Cecilie Hveding, Niels W C J van de Donk, Massimo Offidani, Giuseppe A Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. *J Clin Oncol*. 2021 Nov 10;39(32):3613-3622

- 36 Sandecka V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, Pavlíček P, Jungová A, Kessler P, Wróbel M, Štork M, Štraub J, Pika T, Čápková L, Ševčíková S, Maisnar V, Hájek R. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data. *Neoplasma*. 2022 Dec;69(6):1474-1479.

### Články v recenzovaných a ostatních časopisech

- 1 Benková K, Jelínek T, Hájek R and Koříštek Z. Genomic Alterations in Acute Myeloid Leukemia in Routine Clinical Practice. *Ann Hematol Oncol*. 2022; 9(4): 1405.
- 2 Ondrej Š, Barbora Š, Roman H. Effect of a third booster dose of COVID-19 mRNA vaccine in patients with haematological cancer after the initial two-dose vaccination - a single centre report. *J Vaccines Immunol* 8(1): 029-032.
- 3 Plášek J, Gumulec J, Máca J, Škarda J, Procházka V, Grézl T et al. COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. *The American journal of the medical sciences* 2022; 363(6): 465-475.
- 4 Kaščák, M, Hájek, R., Minařík, J., et al.: Diagnostika a léčba Waldenströmovy makroglobulinemie. Diagnostika a léčba systémové AL amyloidózy: Doporučení vypracovaná Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti, Kooperativní lymfomovou skupinou, Lymfomovou sekcí České hematologické společnosti. *Transfuze a hematologie dnes* 2022; 19 (Supplementum 1): 71 s.
- 5 Mihályová Jana, Jelínek Tomáš, Kaščák Michal, Benková Kateřina, Uraš Juraj, Demel Ivo, Koříštek Zdeněk, Hájek Roman. Practical aspects of CAR-T cell therapy. *Klin Onkol*. 2022 Winter;35(1):44-54.

### Kapitoly v knihách

- 1 M. Formánek, T. Jelínek, T. Blažek. Spolupůsobení lidských papilomavirů s dalšími viry. In M. Formánek et kol. *Respirační papilotomatóza*. ISBN 978 – 80 -7311-207-3
- 2 Bělohlávková P, Hluší A, Ráčil Z, Stejskal L, Ph-negativní myeloproliferativní choroby (esenciální trombocytémie, pravá polycytémie, primární myelofibroza) v Léčebné postupy v hematologii - aktualizace 2022 Doporučení České hematologické společnosti České lékařské společnosti Jana Evangelisty Purkyně, Česká hematologická společnost ČLS JEP, 2022 ISBN 978-80-270-8240-7

### Postery (výběr):

- 1 D. Radhakrishnan, M. Turi, M. Hrdinka. A comprehensive CRISPR-based approach to iden8fy deubiquinases (DUBs) involved in oncogenic processes and cancer. "Ubiquitin and ubiquitin like proteins in health and conference", Cavtat, Croatia, 9/2022
- 2 Chyra, Zuzana; Ševčíková, Tereza; Anilkumar, Anjana Sithara; Vojta, Petr; Adamia, Sophia; Žihala, David; Kapustová, Veronika; Garbová, Nikola; Vrána, Jan; Jelínek, Tomáš; Muroňová, Ludmila; Popková, Tereza; Šimíček, Michal; Hrdinka, Matouš; Hájek, Roman. RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes. 19th International Myeloma Society Annual Meeting. Heidelberg, 9/2022
- 3 Hajek R, Jelinek T, Moreau P, Martin T, Pour L, Mikala G, Symeonidis A, Bringhen S, Rawlings A, Risse ML, van de Velde H. P-196: Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas: IKEMA Subgroup Analysis, Clinical and Leukemia (vol 21, pg S145, 2021). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022 Oct 1;22(10):785-6., IMW, Los Angeles, 8/2022
- 4 Sandecka V, Popkova T, Stork M, Maisnar V, Minarik J, Jungova A, Pavlicek P, Stejskal L, Pospisilova L, Heindorfer A, Obernauerova J. P-177: Outcomes in risk-stratified patients with smoldering multiple myeloma: a retrospective analysis of real-world data from the Czech Registry of Monoclonal Gammopathies. Clinical Lymphoma Myeloma and Leukemia. 2022 Aug 1;22:S132-3., IMW, Los Angeles, 8/2022
- 5 Chyra Z, Ševčíková T, Anilkumar AS, Vojta P, Adamia S, Žihala D, Kapustová V, Garbová N, Vrána J, Jelinek T, Muroňová L. P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes. Clinical Lymphoma, Myeloma and Leukemia. 2022 Aug 1;22:S36-7., IMW, Los Angeles (Young investigator award for poster), 8/2022

- 6 Vlachová M, Štork M, Ševčíková S, Jelínek T, Minařík J, Radocha J et al. P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE. Hemisphere 2022; **6**: 857–858., EHA meeting, Vídeň, 6/2022
- 7 Gumulec Jaromír, Máca Jan, Sagan Jiri, Skarda Jozef, Kutěj Martin, Chobolová Nela, Kaspřák David. Influence of complement system genomic variations on the course of COVID-19. ISTH London, 7/2022
- 8 Gumulec Jaromír, Šimetka Ondřej, Pieczová Alicia, Špaček Richard. Early use of eculizumab in patient with pregnancy-associated atypical haemolytic-uraemic syndrome. ISTH London 7/2022
- 9 Sandecka, Viera, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Hana Lukesova, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros Otero, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Špička. „P-177: Outcomes in Risk-Stratified Patients with Smoldering Multiple Myeloma: A Retrospective Analysis of Real-World Data from the Czech Registry of Monoclonal Gammopathies". Clinical Lymphoma, Myeloma and Leukemia 22:S132–33. 19th International Myeloma Society Annual Meeting, 8/2022
- 10 Zuzana Bilkova, Jakub Radocha, Ludek Pour, Sabina Sevcikova, Roman Hajek, Vladimir Maisnar. Serological proteome analysis identifying autoantibodies against tumor-associated antigen ENO1 as a potential prognostic biomarker in multiple myeloma. 19th International Myeloma Society Annual Meeting in Los Angeles, CA, 8/2022